COMPANY PROFILE

FLX Bio

Focused on the discovery and development of novel small-molecule agents to activate the immune system to eradicate cancer

San Francisco, United StatesFounded 2015Biotech & Life Sciences

Valuation $100–250M Last recorded · 2019

Total funding $100–500M Disclosed equity funding

Unlock exact values

About FLX Bio

RAPT Therapeutics, Inc., formerly known as FLX Bio, is a clinical-stage biopharmaceutical company specializing in immunology. The company focuses on discovering, developing, and commercializing oral small molecule therapies aimed at addressing significant unmet needs in oncology and inflammatory diseases. RAPT Therapeutics operates in the biopharmaceutical market, targeting patients who require advanced treatment options for cancer and chronic inflammatory conditions. The business model revolves around leveraging its proprietary discovery and development engine to create highly selective small molecules, which are then brought through clinical trials and regulatory approval processes. Revenue is generated through the commercialization of these therapies, either independently or through partnerships and licensing agreements with larger pharmaceutical companies. The company serves a niche market of patients with specific medical needs that are not adequately addressed by existing treatments.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2015
Headquarters: San Francisco, United States
Open positions: None listed
Dealroom signal: 19.7/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Developer Tools, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus: b2b
Links: Website

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES COther financing	Jun 2019	$37M	$148M	Undisclosed	—
SERIES COther financing	Dec 2017	$60M	$240M	The Column Group · Kleiner Perkins · Celgene	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

FLX Bio website traffic

Latest recorded traffic for FLX Bio is 200 monthly website visits, down 25.9% over the last three months.

Latest monthly visits200 3-month web change-25.9%

Monthly website visitsMar 2017–Aug 2024

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CPCorvus PharmaceuticalsClinical-stage biopharmaceutical company focused on the development of novel agents that target the immune system to treat patients with cancer	Burlingame, United States	Operational	53	$109M	$1B
BBBiond BiologicsInnovative immunotherapies and a pioneering intracellular delivery for biologics for the treatment of patients	Misgav Am, Israel	Operational
BIBioVendorBioVendor Group is an internationally operating group of companies with its own research & development and manufacturing capability	Brno, Czechia	Acquired
AIApostle IncDevelop technologies to fundamentally improve the efficiency and accuracy of liquid biopsy	Sunnyvale, United States	Operational
ATAvila TherapeuticsFocused on the development of covalent drugs to treat cancer and other autoimmune diseases	Waltham, United States	Acquired
MMMetis Precision MedicineDeveloper of oncologic therapies	Turin, Italy	Operational
OTORCA TherapeuticsPioneer in the development of innovative virotherapies for treatment of cancer	Nijmegen, Netherlands	Operational
SOSoluventisMost powerful therapeutic drug delivery	Bochum, Germany	Operational